中国首个自研双靶点 CAR-T 获批临床

丁香园肿瘤时间
Sep 04, 2025

9 月 4 日,CDE 官网显示,三生制药SA102-CAR-T 注射液获批临床,用于复发难治性多发性骨髓瘤。截图来源:CDE 官网SA102 是思安医疗自主研发的 CS1/BCMA 双靶 CAR-T 产品,也是全球首个获得安全性有效性临床数据的 CS1/BCMA 双靶 CAR-T,有望解决单靶 BCMA CAR-T 在临床应用上存在的局限性。2023 年 12 月,三生制药和思安医疗签署专利授权...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10